Shares of Tourmaline Bio (TRML) after sinking after Roche’s (RHHBY) Chugai Pharmaceutical announced results from its Phase III LUMINESCE study of Enspryng, an investigational treatment for generalized myasthenia gravis. Statistically significant data was observed in its primary endpoint, however the results did not reach expectations on the degree of clinical benefit, the company in a statement. Shares of Tourmaline Bio are down 31%, or $13.95, to $30.72 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TRML:
- Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Tourmaline Bio sees cash runway into 2027
- Tourmaline Bio reports Q4 EPS (81c) vs. ($5.51) last year
- Tourmaline Bio to Present at Upcoming Investor Conferences
- Tourmaline Bio management to meet with Piper Sandler
